Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.
What Is The Predicted Market Size Of The Pediatric Neuroblastoma Treatment Industry By 2029?
There has been robust growth in the pediatric neuroblastoma treatment market in the past few years. The value is anticipated to escalate from $1.85 billion in 2024 to $2.02 billion in 2025, marking an impressive compound annual growth rate (CAGR) of 9.1%. This significant rise during the historical period can be credited to the progression in treatment methods, heightened consciousness and prompt diagnosis, R&D activities, joint ventures, and enhanced survival rates.
In the coming years, robust growth is anticipated in the pediatric neuroblastoma treatment market. It is projected to expand to $2.86 billion by 2029, growing at a compound annual growth rate (CAGR) of 9.1%. The predicted growth during the forecast period can be associated with factors like advanced therapies, personalized medication, worldwide health initiatives, increased availability of treatment, and patient advocacy and support. Key trends for the forecast period include cooperative research efforts, breakthroughs in gene therapy, development of new medications, earlier diagnosis and screening, as well as continued patient advocacy and support.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9924&type=smp
Which Factors Are Steering Growth In The Pediatric Neuroblastoma Treatment Market?
The escalating count of new pediatric neuroblastoma cases is anticipated to spur the expansion of the pediatric neuroblastoma treatment market. The increasing incidence of neuroblastoma boosts the need for alternative pediatric neuroblastoma treatments. This has led to augmented investment in research and development by pharmaceutical companies and other involved entities, fostering innovation in the sector. Additionally, the advent of the latest diagnostic technology and screening methods has facilitated early detection of neuroblastoma, thereby enabling improved treatments and outcomes. For instance, as cited in a March 2023 article by the American Society of Clinical Oncology (ASCO), a US-based association for oncology professionals and doctors, 700 to 800 children are affected by neuroblastoma in the United States annually. In the US, neuroblastoma represents 6% of all child cancers, impacting approximately 90% of children below five years. Hence, the escalating number of new pediatric neuroblastoma cases significantly contributes to the expansion of the pediatric neuroblastoma treatment market.
Which Segment Accounts For The Largest Share In The Pediatric Neuroblastoma Treatment Market?
The pediatric neuroblastoma treatmentmarket covered in this report is segmented –
1) By Treatment Type: Immunotherapy; Chemotherapy; Radiation Therapy; Other Treatment Types
2) By Risk Group: Low Risk; Intermediate Risk; High Risk
3) By End User: Hospitals; Specialty Clinics; Other End Users
Subsegments:
1) By Immunotherapy: Monoclonal Antibodies; Immune Checkpoint Inhibitors; CAR T-Cell Therapy
2) By Chemotherapy: Alkylating Agents; Antimetabolites; Topoisomerase Inhibitors
3) By Radiation Therapy: External Beam Radiation Therapy (EBRT); Radioisotope Therapy
4) By Other Treatment Types: Surgery; Stem Cell Transplantation; Targeted Therapy
What Strategic Shifts And Innovations Are Influencing The Pediatric Neuroblastoma Treatment Market?
Leading businesses in the pediatric neuroblastoma treatment market are pioneering technologies such as antibody technologies to bolster the effectiveness of targeted therapies and enhance patient prognosis. Antibody technologies comprise a range of techniques and instruments used for the creation, production, and usage of antibodies in diagnostics, therapeutics, and research. As an illustration, Renaissance Pharma Ltd, a clinical-stage biopharmaceutical enterprise based in the UK, unveiled Hu14.18K322A in August 2023. Hu14.18K322A is designed to target GD2, a disialoganglioside found on the surface of neuroblastoma cells. By attaching to these cells, it prompts immune effector cells to assault and eliminate the tumor cells, potentially augmenting treatment results for patients with high-risk neuroblastoma.
Who Are The Dominant Players In The Pediatric Neuroblastoma Treatment Market Today?
Major companies operating in the pediatric neuroblastoma treatment market include United Therapeutics Corporation, APEIRON Biologics AG, Baxter International Inc., Cell Ectar Biosciences Inc., Pfizer Inc., MacroGenics Inc., Bayer AG, Provectus Biopharmaceuticals Inc., Sartorius AG, Y-mAbs Therapeutics Inc., Amgen Inc., Eli Lilly and Company, F. Hoffmann-La Roche AG, Clarity Pharmaceuticals, CureSearch for Children’s Cancer, Novartis AG, Johnson & Johnson Services Inc., AbbVie Inc., Merck & Co. Inc., Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Daiichi Sankyo Company Limited, Eisai Co. Ltd.
Access The Complete Report Here:
What Regional Factors Are Accelerating Growth In The Pediatric Neuroblastoma Treatment Market?
North America was the largest region in the pediatric neuroblastoma treatment market in 2024. The regions covered in the pediatric neuroblastoma treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=9924&type=smp
Browse Through More Reports Similar to the Global Pediatric Neuroblastoma Treatment Market 2025, By The Business Research Company
Gastrointestinal Bleeding Treatment Devices Global Market Report 2025
Gastrointestinal Devices Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/gastrointestinal-devices-global-market-report
Medical Equipment Maintenance Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/medical-equipment-maintenance-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model